A high complete remission (CR) rate has been reported in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph þ ALL) following imatinib-based therapy. However, the overall effect of imatinib on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is undetermined. Between 2002 and 2005, 100 newly diagnosed adult patients with Ph þ ALL were registered to a phase II study of imatinib-combined chemotherapy (Japan Adult Leukemia Study Group Ph þ ALL202 study) and 97 patients achieved CR. We compared clinical outcomes of 51 patients who received allo-HSCT in their first CR (imatinib cohort) with those of 122 historical control patients in the pre-imatinib era (pre-imatinib cohort). The probability of overall survival at 3 years after allo-HSCT was 65% (95% confidence interval (CI), 49-78%) for the imatinib cohort and 44% (95% CI, 35-52%) for the pre-imatinib cohort. Multivariate analysis confirmed that this difference was statistically significant (adjusted hazard ratio, 0.44, P ¼ 0.005). Favorable outcomes of the imatinib cohort were also observed for disease-free survival (P ¼ 0.007) and relapse (P ¼ 0.002), but not for non-relapse mortality (P ¼ 0.265). Imatinib-based therapy is a potentially useful strategy for newly diagnosed patients with Ph þ ALL, not only providing them more chance to receive allo-HSCT, but also improving the outcome of allo-HSCT.
Introduction
The Philadelphia chromosome (Ph) presents in 20-25% of adult patients with acute lymphoblastic leukemia (ALL) and is an extremely unfavorable prognostic factor. The outcome of patients with Ph-positive ALL (Ph þ ALL) following conventional chemotherapy is dismal, showing o20% long-term survival. [1] [2] [3] [4] Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) has offered a curative option in Ph þ ALL, [3] [4] [5] relatively high rates of relapse and non-relapse mortality (NRM) impair the treatment success even after allo-HSCT. The International Bone Marrow Transplant Registry reported a leukemia-free survival rate of 38% following human leukocyte antigen (HLA)-identical allo-HSCT for Ph þ ALL patients transplanted in the first complete remission (CR). 6 Previously, we and others reported that imatinib-based chemotherapy produced very high CR rate, thus allowing a high proportion of patients to prepare for allo-HSCT. 7, 8 However, because of the short observation period, the impact of imatinib-based therapy upon the survival outcomes after allo-HSCT remains unclear. To address whether allo-HSCT after imatinib-based therapy is a superior treatment approach to that after conventional chemotherapy, we conducted a retrospective analysis of Ph þ ALL patients who underwent allo-HSCT before and after imatinib became available, using data from the Japan Adult Leukemia Study Group (JALSG) Ph þ ALL202 study and from the nationwide database of the Japan Society of Hematopoietic Stem-cell Transplantation (JSHCT) and the Japan Marrow Donor Program (JMDP).
Patients and methods

Data source and patient selection criteria
We compared the transplantation outcome of patients treated by the JALSG Ph þ ALL 202 study (imatinib cohort) with those in the historical control data in the pre-imatinib era from the JSHCT and JMDP (pre-imatinib cohort), in which information on patient survival, disease status and long-term complications, including chronic graft-versus-host disease (cGVHD) and second malignancies, is renewed annually using follow-up forms. 9, 10 To attain an adequate level of comparability in terms of allo-HSCT, patients were selected according to the following criteria: (1) patients with de novo Ph þ ALL; (2) age range of 15-65 years and (3) allo-HSCT during their first CR. A total of 122 patients who received allo-HSCT between January 1995 and December 2001 (before the approval of imatinib by the Japanese government) were selected. This study period of the pre-imatinib cohort included the pioneering period of cord blood transplantation (CBT) when the relevance of cell dose and HLA matching
had not yet been recognized. Thus, the subjects were limited to those who received bone marrow (BM) or peripheral blood (PB) as a treatment graft.
Patients
Between September 2002 and May 2005, 100 newly diagnosed patients with Ph þ ALL were registered to the JALSG Ph þ ALL202 study, and received a phase 2 imatinib-combined chemotherapy as described previously. 7 Ph þ ALL was diagnosed by the presence of Ph through chromosome and/or FISH analysis, and positivity for BCR-ABL fusion transcripts detection by real-time quantitative polymerase chain reaction (RQ-PCR) analysis.
Of 97 patients who achieved CR, 60 patients received allo-HSCT in their first CR. Of these 60 patients, 9 patients who received unrelated CBT were excluded in this analysis because of the reason as described at the selection criteria for control patients in the pre-imatinib era. Thus, 51 patients transplanted between February 2003 and December 2005 were analyzed. In the JALSG Ph þ ALL202 study, allo-HSCT was recommended after achieving CR if an HLA-identical donor was available. The stem cell source for allo-HSCT was chosen in the following order: (1) matched-related allo-HSCT; (2) HLA-A, B and DRB1 allele matched (6/6) or DRB1 one-allele mismatched-unrelated allo-BMT, if patients had no HLA-matched-related donor and (3) unrelated CBT or HLA-mismatched-related allo-HSCT, if they had no donors described in (1) and (2) . A prophylaxis for GVHD was determined by each institute, but did not include T-cell depletion. The study was approved by the institutional review board of each participating center and conducted in accordance with the Declaration of Helsinki.
Definition of engraftment and GVHD
Engraftment day was defined as the first day of three consecutive days when the absolute neutrophil count was X0.5 Â 10 9 /l. Graft failure was defined as the lack of any sign of neutrophil recovery. Engraftment that occurred after day 60 was also considered to be a graft failure. Patients who died early (oday 29) were excluded from the analysis of engraftment. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were defined according to previously described standard criteria.
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Quantitation of BCR-ABL transcripts
The copy number of BCR-ABL transcripts in BM was determined at a central laboratory using the RQ-PCR as described previously. 7 To minimize the variability in the results because of differences in the efficiency of cDNA synthesis and RNA integrity among the patient samples, the copy number of the BCR-ABL transcripts was converted to molecules per microgram RNA after being normalized by means of GAPDH. The normalized values of the BCR-ABL copies in each sample were reported as BCR-ABL number of copies. At least 5.7 Â 10 5 copies/mg RNA GAPDH levels were required in a sample to consider a negative PCR result valid; otherwise, the sample was not useful for minimal residual studies. The threshold for quantification was 50 copies/mg RNA. The levels below this threshold were designated as 'not detected' or 'o50 copies/mg'. In this study, the former was categorized as PCR negativity.
Minimal residual disease (MRD) at the time of HSCT was evaluated by the result of RQ-PCR within 30 days prior to transplantation.
Statistical considerations
The primary end point of this study was overall survival (OS) after allo-HSCT. Secondary end points included disease-free survival (DFS) and the incidence of aGVHD, cGVHD, NRM and relapse. We defined DFS events as relapse or death, whichever occurred earlier. The observation periods for OS were calculated from the date of transplantation until the date of the event or last known date of follow-up. The probabilities of OS and DFS were estimated using the Kaplan-Meier product limit method. The cumulative incidences of NRM, relapse, aGVHD and cGVHD were estimated as described elsewhere, taking the competing risk into account. 12 In each estimation of the cumulative incidence of an event, death without an event was defined as a competing risk. Risk factors for OS and DFS were evaluated by a combination of uni-and multivariate analyses. The following variables were evaluated for each analysis: imatinib-based therapy prior to HSCT, age group (under 40 versus 40 to 54 versus 55 and older), stem cell source (BM versus PB), HLA disparity (matched (HLA-identical siblings or 6/6 allele matched unrelated) versus mismatched), duration from diagnosis to HSCT and cGVHD as time-varying covariate (yes versus no). Univariate analysis was performed using Cox regression models or log-rank test. Multivariate analysis was performed using Cox proportional hazards regression model or competing risk regression model 13 as appropriate. For the evaluation of time-varying events, such as aGVHD or cGVHD, upon clinical outcomes, we treated these as time-varying covariates. Differences among groups in terms of demographic characteristics were tested using the w 2 or Mann-Whitney tests as appropriate. All statistical analyses were conducted using STATA 11 (STATA Corp., College Station, TX, USA).
Results
Patient characteristics
In the imatinib cohort, there were 29 males and 22 females, with a median age of 38 years (range, 15-64 years). Regarding transcript types, 36 patients had minor BCR-ABL and 15 had major BCR-ABL. In 5 patients, pre-treatment cytogenetic data were not available, and of the remaining 46 patients, 8 showed t(9;22) only, 36 had additional chromosome aberrations and 2 showed normal karyotype. Of 48 patients who were evaluable for MRD analysis, 36 patients achieved PCR negativity at the time of HSCT.
Some of the clinical and biological features (such as presence of additional chromosome aberrations, BCR-ABL subtype, MRD status at HSCT and performance status at HSCT) were not available in the pre-imatinib cohort and not included in the present analysis. Table 1 lists the characteristics of patients included in this comparative analysis. Some of the clinical features were significantly different between two cohorts: age distribution at HSCT (P ¼ 0.048), conditioning regimens (Po0.001), GVHD prophylaxis (Po0.001) and duration from diagnosis to HSCT (P ¼ 0.041). The majority of patients received the preparatory regimen of total body irradiation followed by cyclophosphamide and/or cytarabine. Five patients aged 455 in the imatinib cohort were given a reduced intensity regimen consisting of fludarabine and melphalan or busulfan. In the pre-imatinib cohort, a combination of cyclosporine (CsA) and short-term methotrexate (sMTX) was mostly used in the prophylaxis of GVHD. On the other hand, both CsA þ sMTX and tacrolimus (FK506) þ sMTX combinations were commonly used in the imatinib cohort. In both cohorts, none of the patients received imatinib therapy after HSCT in their first CR. In the imatinib cohort, all patients who showed hematologic relapse after HSCT received salvage treatment comprising of imatinib and/or chemotherapy. As for the pre-imatinib cohort, 13 patients relapsed after the approval of imatinib by the Japanese government (beyond December 2001). However, we have no information on how many patients received imatinib-based therapy after their relapse. The median follow-up period for survivors was 2.6 years (range, 1.0-4.6 years) for the imatinib cohort and 6.9 years (range, 0.1-11.4 years) for the pre-imatinib cohort.
Outcome OS and DFS. In the pre-imatinib cohort, 80 patients died after HSCT: 46 of disease recurrence and 34 of causes other than leukemia. In the imatinib cohort, 35 patients were alive, 32 of them were free of leukemia and 16 patients died after HSCT: 4 of disease recurrence and 12 of causes other than leukemia. The 3-year OS was 65% (95% confidence interval (CI), 49-78%) for the imatinib cohort and significantly higher than 44% (95% CI, 35-52%) for the pre-imatinib cohort (P ¼ 0.0148; Figure 1a) . The 3-year DFS was 58% (95% CI, 41.8-70.9%) for the imatinib cohort and significantly higher than 37% (95% CI, 28.5-45.6%) for the pre-imatinib cohort (P ¼ 0.039; Figure 1b) . Table 2 shows the result of risk factor analysis for OS and DFS among all 173 patients. In the multivariate analysis, the only variable found to influence OS and DFS was the pre-transplant imatinib-based therapy (hazard ratio (HR) ¼ 0.44 (95% CI, 0.25-0.77); P ¼ 0.004 and HR ¼ 0.51 (95% CI, 0.31-0.86); P ¼ 0.011, respectively). The presence of cGVHD showed a tendency of favorable OS and DFS, but did not reach the statistical significance (HR ¼ 0.66 (95% CI, 0.42-1.06); P ¼ 0.085 and HR ¼ 0.75 (95% CI, 0.47-1.19); P ¼ 0.217, respectively).
Other outcomes of transplantation Relapses. In the pre-imatinib cohort, 48 patients relapsed after HSCT with a median of 240 days (range, 42-2302 days).
In the imatinib cohort, 7 patients (3 of 36 with PCR negative and 4 of 12 with PCR positive at HSCT) relapsed after HSCT with a median of 137 days (range, 68-728 days). The estimated cumulative incidence of relapse at 3 years was 15.0% (95% CI, 6.6-26.7%), and significantly lower than that of the pre-imatinib cohort (50.4% at 3 years (95% CI, 39.6-60.2%); P ¼ 0.002; Figure 1c ). Among patients in the imatinib cohort, patients with PCR negative showed significantly lower relapse rate compared with that of PCR positive (10.0% (95% CI, 2.5-23.6%) versus 41.3% (95% CI, 16.9-64.4%) at 3 years, respectively, P ¼ 0.025).
Non-relapse mortality. In the pre-imatinib cohort, 34 patients died of non-relapse causes at a median of 159 days (range, 5-2094 days) after HSCT. The estimated cumulative incidence of NRM in the pre-imatinib cohort was 28% (95% CI, 20-36) at 3 years (Figure 2a ). In the imatinib cohort, 12 patients died of non-relapse causes at a median of 329 days (range, 41-850 days) after HSCT. The 3-year cumulative incidences of NRM were 21% (95% CI, 11-33%; Figure 2a ). There were no significant differences between two cohorts (P ¼ 0.265).
Cause of death. Recurrence of the primary disease was the leading cause of death in both groups: 55% for the pre-imatinib cohort and 25% for the imatinib cohort. In the pre-imatinib cohort, the causes of NRM were organ failure (11%), infection (9%), GVHD (8%), transplantation-associated thrombotic microangiopathy (TMA) (4%), interstitial pneumonia (3%), graft failure (3%) and other causes (6%). In the imatinib cohort, the causes of NRM included infection (19%), bronchiolitis obliterans with organizing pneumonia (13%), TMA (13%), GVHD (13%), organ failure (6%) and other causes (12%).
Graft-versus-host disease. There was no significant difference in the cumulative incidence of Grades 2-4 aGVHD between two cohorts (31% (95% CI, 19-44%) versus 37% (95% CI, 29-46%), P ¼ 0.391; Figure 2b ). The cumulative incidence of cGVHD at 1 year after HSCT was significantly higher in the imatinib cohort than in the pre-imatinib cohort (49% (95% CI, 31-64%) versus 27% (95% CI, 18-37%), P ¼ 0.0261; Figure 2c ). Allogeneic HSCT for Ph þ ALL in imatinib era S Mizuta et al However, regarding the cumulative incidence of extensive-type cGVHD, there was no significant difference between two cohorts (22% (95% CI, 10-36%) versus 12% (95% CI, 6-20%), P ¼ 0.119; Figure 2d ).
Association between cGVHD and OS/DFS/relapse. To examine the difference of impacts of cGVHD upon clinical outcome in the pre-and imatinib cohorts, we conducted stratified analysis by cohort, treating cGVHD as a time-varying covariate (Table 3 ). Multivariate analysis revealed that, in the imatinib cohort, there were no significant associations between cGVHD and OS/DFS/relapse (P ¼ 0.707, 0.332 and 0.713, respectively). On the other hand, in the pre-imatinib cohort, there was a significant association between cGVHD and OS (HR ¼ 0.59 (95% CI, 0.35-1.00), P ¼ 0.048), but not between cGVHD and DFS/relapse (P ¼ 0.234 and 0.338, respectively).
Engraftment. In the pre-imatinib cohort, three patients experienced graft failure. The median periods to reach the neutrophil count of 40.5 Â 10 6 /l and platelet count of 50 Â 10 6 /l were 15 days (range, 8-49 days) and 25 days (range, 9-120 days), respectively, for evaluable patients. In the imatinib cohort, all 51 patients were engrafted. The median period to reach a neutrophil count of 40.5 Â 10 6 /l and platelet count of 50 Â 10 9 /l was 15 days (range, 5-41 days) and 25 days (range, 11-504 days), respectively, for evaluable patients. There was no Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; CI, confidence interval; cGVHD, chronic graft-versus-host disease; HLA, human leukocyte antigen; HSCT, hemtopoetic stem cell transplantation; PB, peripheral blood; Ph, Philadelphia chromosome; RE, related; RR, relative risk; UR, unrelated.
Allogeneic HSCT for Ph þ ALL in imatinib era S Mizuta et al significant difference in neutrophil and platelet recovery between two cohorts (P ¼ 0.201 and 0.783, respectively).
Discussion
This study showed that patients with Ph þ ALL who achieved CR by imatinib-based therapy and subsequently received allo-HSCT in their first CR showed significantly superior survival outcome to those in the pre-imatinib era. To our knowledge, our current report is the first to describe the superiority of imatinib-based therapy for this disease by analyzing a substantial number of patients with sufficient follow-up period. The treatment of Ph þ ALL has changed dramatically since the introduction of imatinib and 490% of patients have achieved CR, 7, 14, 15 and allows SCT to be performed in a substantial proportion of patients in major or complete molecular remission. 8, [16] [17] [18] Actually, in the imatinib cohort, 97 of 100 patients (97%) achieved CR and 60 (60%) could receive allo-HSCT in their first CR. Several studies reported improved OS rates compared with that in the pre-imatinib era by incorporation of imatinib-based therapy. 14, 15, 19, 20 However, there had been few reports focusing on the clinical impact of pre-transplant imatinib administration on the outcome of HSCT. Lee et al. 8 reported superior outcome of HSCT by imatinib-based therapy compared with the historical control data, in which 29 patients with prior imatinib treatment showed better outcomes in terms of relapse, DFS and OS than the historical control patients. However, their comparative analysis included patients who received HSCT for refractory disease or beyond their first CR (4 of 29 patients in the imatinib group and 16 of 33 patients in the historical group). Several studies showed that remission status at the time of HSCT was one of the most important prognostic factors for outcome.
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Therefore, we contend that it would be better to assess a greater number of patients and exclude patients with advanced stage at HSCT to accurately compare the clinical impact of imatinibbased therapy on the outcome of HSCT. To our knowledge, this study has the largest number of Ph þ ALL patients receiving allo-HSCT in their first CR with the longest follow-up duration yet reported. It is noteworthy from our findings that a lower rate of relapse was found in the imatinib cohort. Our results thus suggest that an imatinib-based therapy provides a survival benefit for newly diagnosed Ph þ ALL patients by lowering the rate of subsequent relapse after HSCT. Despite the lack of comparative data of MRD in the pre-imatinib cohort, 75% of patients in the imatinib cohort achieved RQ-PCR negativity for BCR/ABL at the time of HSCT. Moreover, the relapse rate was significantly lower among Abbreviations: CI, confidence interval; cGVHD, chronic graft-versus-host disease; DFS, disease-free survival; HLA, human leukocyte antigen; OS, overall survival; PBSC, peripheral blood stem cell. Data were adjusted for age categories, donors from unrelated subjects, HLA-matching status, PBSC graft and days to transplantation. Cox proportional hazard models were applied to OS and DFS, and a competing risk regression model was applied to relapse.
patients with PCR negative. From these, we believe that a powerful anti-leukemia activity of the imatinib-based therapy mostly contributed to the prevention of subsequent relapse after HSCT in the present analysis. Thinking of the reduced relapse rate after HSCT, impact of cGVHD should also be considered. Several studies in the pre-imatinib era reported beneficial impact of cGVHD on relapse incidence and survival. [23] [24] [25] In this study, the incidence of cGVHD was significantly higher in the imatinib cohort compared with that in the pre-imatinib cohort. In the imatinib cohort, more patients received PB as a stem cell source, which might have contributed to the high frequency of cGVHD. Besides, longer leukemia-free survival period in the imatinib cohort might have contributed to the increased frequency of cGVHD, which is a late complication often observed in the recipients of allo-HSCT who had survived without disease for at least 3 months after transplantation. One could argue that this observation could be related to a stronger graft versus leukemia effect and contribute to the lower relapse rate. However, the presence of cGVHD had no significant impact on the OS/DFS/relapse rate in our imatinib cohort by multivariate analysis.
To assist the proper interpretation of our current results, the strengths and limitations need to be considered. As discussed earlier, one of the strengths of this study is the large sample size for the imatinib cohort, which gives us a better estimation of the end points and also adds statistical power to the analyses. In addition, adjustments for potential confounders in the comparisons with the pre-imatinib cohort from a nationwide registry allow unbiased estimates to be made, at least in Japan. Given the evidence for a substantial impact of imatinib in Ph þ ALL patients, 7, [14] [15] [16] it is unrealistic to conduct a prospective study comparing treatments with or without imatinib. Hence, a retrospective cohort design could be suboptimal to address the key questions.
One of the possible limitations of our current analysis could be the presence of residual confounding factors both of known and unknown. Among the known factors, a difference in the conditioning regimens could be noted. The City of Hope National Medical Center reported a favorable result from the use of a fractionated TBI-etoposide regimen in the treatment of Ph þ ALL. 26 However, in the comparative analysis, the clinical advantage of this approach seemed to be established mostly among patients transplanted in their second CR. 27 Moreover, this approach was commonly applied in our pre-imatinib cohort rather than in the imatinib cohort (22 and 4%, respectively) . Differences in GVHD prophylaxes should also be considered. Tacrolimus was more frequently used in the imatinib cohort than in the pre-imatinib cohort, which reflects the change in practice within the field of allo-HCT in Japan as tacrolimus was widely used for unrelated allo-HSCT since 2000. Nevertheless, the lack of any differences in the incidence of aGVHD between two cohorts indicates that this factor had minimal impact in our analysis.
It may be argued that the improved outcome of the imatinib cohort have been influenced by the pre-transplant chemotherapy in the JALSG Ph þ ALL 202 study. Although detailed information on the pre-transplant chemotherapy in the preimatinib cohort was not available, it was clear that the majority of patients were most likely treated by the JALSG ALL93 or JALSG ALL97 protocols as pre-transplant chemotherapy, 2 as these were widely used regimens in Japan at the time. The chemotherapeutic regimen in the JALSG Ph þ ALL202 study was similar to those used in these protocols. Thus, the effectiveness on Ph þ ALL would have been similar between the two cohorts. At least in JALSG, there had been neither remarkable progress in the chemotherapy of Ph þ ALL until the clinical introduction of imatinib, nor in other groups including the MD Anderson Cancer Center. 28 Thus, in the present analysis, the influence of pre-transplant chemotherapy appears to be quite limited.
The difference of transplant year between the two cohorts (1995-2001 and 2002-2005 , respectively) could have affected the outcome of HSCT, and the improvement of transplantation procedure might have contributed to the favorable outcome in the imatinib cohort. However, Nishiwaki et al. 29 analyzed the clinical outcome of 641 Japanese patients with Ph-negative ALL who had received allo-HSCT in their first CR in 1993-1997, 1998-2002 and 2003-2007 , and reported that there was no statistical difference in OS and NRM between three periods. In this study, the incidence of NRM was lower in the imatinib cohort, but did not reach the statistical significance. Therefore, the influence of transplantation year is thought to be limited in this study.
Considering potential benefit by imatinib, the lack of information about post-transplant imatinib use in the pre-imatinib cohort might have led us to underestimate the difference between two cohorts.
In conclusion, we have found that there is a significant improvement in the OS and DFS of Ph þ ALL patients who received allo-HSCT following imatinib-based therapy. Although further validation using larger cohorts from different populations is essential to confirm our findings, imatinib-based therapy is likely to be a useful strategy for not only giving patients with Ph þ ALL more chance to receive allo-HSCT, but also for improving their outcome after allo-HSCT.
